Literature DB >> 22377677

Disappearance of association in diabetic patients on hemodialysis between anemia and mortality risk: the Japan dialysis outcomes and practice pattern study.

Masaaki Inaba1, Yasuaki Hayashino, Tetsuo Shoji, Takashi Akiba, Tadao Akizawa, Akira Saito, Kiyoshi Kurokawa, Shunichi Fukuhara.   

Abstract

We previously demonstrated that anemia was not associated with mortality in hemodialysis patients with cardiovascular disease (CVD). Since diabetes mellitus (DM) accelerates CVD, the influence of DM on the relationship between anemia and mortality was examined using the data obtained from 1,385 DM patients and 2,583 non-DM hemodialysis patients recruited into the Dialysis Outcomes Practice Pattern Study in Japan (J-DOPPS). When all patients were stratified into four groups on their hematocrit levels, mortality rate was significantly and steadily lower in the subgroups with the higher levels of hematocrit by the Kaplan-Meier method (p = 0.0003 by log-rank test). When DM and non-DM patients were analyzed separately, a significant association of lower hematocrit levels with higher mortality disappeared in DM patients (p = 0.6280), in contrast with its retention in non-DM counterparts (p < 0.0001). Multivariable-adjusted Cox proportional hazards models demonstrated a significant association between hematocrit with all-cause mortality in non-DM patients after adjustment for age, gender, BMI, hemodialysis duration, SBP, DBP, albumin, total cholesterol, calcium, phosphorus, and intact PTH (p = 0.046), whereas this association disappeared in DM patients in the same model (p = 0.583). In conclusion, these results suggested that the association between anemia and higher mortality disappeared in DM hemodialysis patients, in contrast with non-DM counterparts.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22377677     DOI: 10.1159/000335979

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  9 in total

1.  Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia.

Authors:  Takashi Maruyama; Terumi Higuchi; Toshio Yamazaki; Erina Okawa; Hideyuki Ando; Osamu Oikawa; Atsushi Inoshita; Kazuyoshi Okada; Masanori Abe
Journal:  Cardiorenal Med       Date:  2017-04-20       Impact factor: 2.041

2.  Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial.

Authors:  Tadao Akizawa; Masaomi Nangaku; Takuhiro Yamaguchi; Masanobu Arai; Ryosuke Koretomo; Kazuo Maeda; Yuya Miyazawa; Hideki Hirakata
Journal:  Nephron       Date:  2019-05-22       Impact factor: 2.847

3.  Association between anemia and mortality in hemodialysis patients is modified by the presence of diabetes.

Authors:  Yukio Maruyama; Eiichiro Kanda; Kan Kikuchi; Masanori Abe; Ikuto Masakane; Takashi Yokoo; Kosaku Nitta
Journal:  J Nephrol       Date:  2021-02-08       Impact factor: 3.902

4.  A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study.

Authors:  Tadao Akizawa; Masaomi Nangaku; Takuhiro Yamaguchi; Ryosuke Koretomo; Kazuo Maeda; Yuya Miyazawa; Hideki Hirakata
Journal:  Kidney Dis (Basel)       Date:  2021-07-05

5.  Parathyroid Hormone Serum Levels and Mortality among Hemodialysis Patients in the Gulf Cooperation Council Countries: Results from the DOPPS (2012-2018).

Authors:  Issa Al Salmi; Brian Bieber; Mona Al Rukhaimi; Ali AlSahow; Faissal Shaheen; Saeed M G Al-Ghamdi; Jamal Al Wakeel; Fadwa Al Ali; Ali Al-Aradi; Fayez Al Hejaili; Yacoub Al Maimani; Essam Fouly; Bruce M Robinson; Ronald L Pisoni
Journal:  Kidney360       Date:  2020-08-26

6.  Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients.

Authors:  Norio Hanafusa; Takanobu Nomura; Takeshi Hasegawa; Masaomi Nangaku
Journal:  Nephrol Dial Transplant       Date:  2014-08-21       Impact factor: 5.992

7.  Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study.

Authors:  Tatsunori Toida; Takashi Iwakiri; Yuji Sato; Hiroyuki Komatsu; Kazuo Kitamura; Shouichi Fujimoto
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

8.  The clinical significance and risk factors of anti-platelet factor 4/heparin antibody on maintenance hemodialysis patients: a two-year prospective follow-up.

Authors:  Delong Zhao; Xuefeng Sun; Li Yao; Hongli Lin; Jijun Li; Jiuyang Zhao; Zhimin Zhang; Lide Lun; Jianrong Zhang; Mingxu Li; Qi Huang; Yang Yang; Shimin Jiang; Yong Wang; Hanyu Zhu; Xiangmei Chen
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

9.  The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients.

Authors:  Owen Kwon; Hye Min Jang; Hee-Yeon Jung; Yon Su Kim; Shin-Wook Kang; Chul Woo Yang; Nam-Ho Kim; Ji-Young Choi; Jang-Hee Cho; Chan-Duck Kim; Yong-Lim Kim; Sun-Hee Park
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.